Drugmakers with White House MFN Deals Claim Exemption from Proposed Medicare Pricing Tests
Several of the 14 pharmaceutical companies that struck individual drug-pricing deals with the White House, aligning U.S. prices with most-favored-nation (MFN) rates, claim exemption from new Medicare pilot programs aimed at lowering prices.4
These exemptions may undermine the Medicare demonstrations, potentially depriving patients of cheaper drugs, as terms of the deals remain undisclosed.4
Recent deals include nine new agreements announced around December 2025, providing state Medicaid programs access to MFN prices and deep discounts for consumers.136
Trump administration's MFN efforts, revived via Executive Order in May 2025, involve voluntary pacts with companies like Pfizer, AstraZeneca, Eli Lilly, and Novo Nordisk for lower prices in Medicare, Medicaid, and direct-to-consumer sales.28
Sources:
1. https://www.aha.org/news/headline/2025-12-19-administration-reaches-deals-9-drug-companies-lower-drug-costs
2. https://www.amcp.org/letters-statements-analysis/federal-update-trump-administration-announces-deal-bring-most-favored-nation-pricing-glp-1s
3. https://www.whitehouse.gov/fact-sheets/2025/12/fact-sheet-president-donald-j-trump-announces-largest-developments-to-date-in-bringing-most-favored-nation-pricing-to-american-patients/
4. https://www.statnews.com/2025/12/23/trump-drug-pricing-deals-medicare-most-favored-nation-demos/
6. https://www.ajmc.com/view/trump-strikes-9-new-pricing-agreements-as-drugmakers-navigate-tariff-regulatory-pressure
8. https://www.pharmaceutical-technology.com/analyst-comment/transforming-us-drug-access-production-mfn-pricing-deals-historic-manufacturing-investments/